B1B: Patient Preferred

The VersaFoam Advantage

Optimizes delivery

Patient preference

Compliance

Suitable for multiple body areas

Easy to apply

Scientific Data

Bibliography

References:

2 Gottlieb AB, Odom Ford R, Spellman MC. The Efficacy and Tolerability of Clobetasol Propionate Foam 0.05% in the Treatment of Mild to Moderate Plaque-type Psoriasis of Nonscalp Regions. J Cut Med Surgery: 2003:7:185-192. (see pages 190-192)

3 Data on file, Stiefel Laboratories

Patient preference2

Patients who were part of studies testing medications formulated in VERSAFOAM HF or EF completed post-study surveys about formulation preferences. Many patients rated VERSAFOAM qualities like ease of use, absorption, and soft feel as better than traditional formulations they had used in the past (lotions, creams etc.), and indicated a preference for the VERSAFOAM vehicle. These study patients were being treated for skin conditions including eczema and psoriasis.

VERSAFOAM-HF™
Patients prefer VERSAFOAM-HF vs. other formulations2

*Based on a post-study questionnaire using a 1-5 scale; percent of patients using clobetasol propionate foam who thought foam was significantly superior or superior to other formulations (gel, creams and ointment).

VERSAFOAM-EF™
Patient Preference Evaluation: VERSAFOAM-EF vs. other vehicles3

Based on post-study questionnaires, the proportion of respondents who feel foam is "much better than" or "better than" the specified skin medicine. OLUX-E (clobetasol propionate) Foam, 0.05% Study: Moderate-Severe Atopic Dermatitis; VERDESO (desonide) Foam, 0.05% Study: Mild-Moderate Atopic Dermatitis.